Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Boyer

Showing results (381-390 of 428) with videos related to

Pageof 43
Sort By:
AJNR. American Journal of Neuroradiology|June 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
AJNR. American Journal of Neuroradiology|May 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
AJNR. American Journal of Neuroradiology|April 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
Cornea|February 1, 2018
Effects of Repeated Intravitreal Aflibercept Injection on the Corneal Endothelium in Patients With Age-Related Macular Degeneration: Outcomes From the RE-VIEW StudyJonathan H Lass, Beth Ann Benetz, Harry J Menegay, et al.
AJNR. American Journal of Neuroradiology|August 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
AJNR. American Journal of Neuroradiology|September 20, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
Pharmacoeconomics - Open|July 6, 2019
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central AfricaS Boyer, M L Nishimwe, L Sagaon-Teyssier, et al.
Ophthalmology|February 27, 2009
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degenerationPeter K Kaiser, , David S Boyer, et al.
Ophthalmology. Retina|May 4, 2019
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME StudiesPaul Mitchell, Ian McAllister, Michael Larsen, et al.
Ophthalmology|May 28, 2013
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDEDavid M Brown, Quan Dong Nguyen, Dennis M Marcus, et al.
Pageof 43

Showing results (381-390 of 428) with videos related to

Sort By:
Pageof 43
AJNR. American Journal of Neuroradiology|June 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
AJNR. American Journal of Neuroradiology|May 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
AJNR. American Journal of Neuroradiology|April 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
Cornea|February 1, 2018
Effects of Repeated Intravitreal Aflibercept Injection on the Corneal Endothelium in Patients With Age-Related Macular Degeneration: Outcomes From the RE-VIEW StudyJonathan H Lass, Beth Ann Benetz, Harry J Menegay, et al.
AJNR. American Journal of Neuroradiology|August 1, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
AJNR. American Journal of Neuroradiology|September 20, 1997
Annotated bibliographyN Altman, R S Boyer, J A Brunberg, et al.
Pharmacoeconomics - Open|July 6, 2019
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central AfricaS Boyer, M L Nishimwe, L Sagaon-Teyssier, et al.
Ophthalmology|February 27, 2009
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degenerationPeter K Kaiser, , David S Boyer, et al.
Ophthalmology. Retina|May 4, 2019
Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME StudiesPaul Mitchell, Ian McAllister, Michael Larsen, et al.
Ophthalmology|May 28, 2013
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDEDavid M Brown, Quan Dong Nguyen, Dennis M Marcus, et al.
Pageof 43